Suprax® (Tablets, Capsules, Granules) Instructions for Use
ATC Code
J01DD08 (Cefixime)
Active Substance
Cefixime (Rec.INN registered by WHO)
Clinical-Pharmacological Group
Third generation cephalosporin
Pharmacotherapeutic Group
Antibiotic-cephalosporin
Pharmacological Action
A broad-spectrum semi-synthetic third-generation cephalosporin antibiotic for oral administration. It acts bactericidally. The mechanism of action is due to the inhibition of the synthesis of the pathogen’s cell membrane. Cefixime is resistant to the action of β-lactamases produced by most gram-positive and gram-negative bacteria.
In vitro, Cefixime is active against gram-positive bacteria Streptococcus agalactiae; gram-negative bacteria Haemophilus parainfluenzae, Proteus vulgaris, Klebsiella pneumoniae, Klebsiella oxytoca, Pasteurella multocida, Providencia spp., Salmonella spp., Shigella spp., Citrobacter amalonaticus, Citrobacter diversus, Serratia marcescens.
In vitro and in clinical practice, Cefixime is active against gram-positive bacteria Streptococcus pneumoniae, Streptococcus pyogenes; gram-negative bacteria Haemophilus influenzae, Moraxella (Branhamella) catarrhalis, Escherichia coli, Proteus mirabilis, Neisseria gonorrhoeae.
The following are resistant to cefixime: Pseudomonas spp., Enterococcus (Streptococcus) serogroup D, Listeria monocytogenes, most Staphylococcus spp. (including methicillin-resistant strains), Enterobacter spp., Bacteroides fragilis, Clostridium spp.
Pharmacokinetics
When taken orally, the bioavailability of cefixime is 40-50% regardless of food intake; however, the Cmax of cefixime in serum is reached 0.8 hours faster when the drug is taken with food. Plasma protein binding, mainly with albumin, is 65%. About 50% of the dose is excreted in the urine unchanged within 24 hours, about 10% of the dose is excreted in the bile.
The T1/2 is dose-dependent and is 3-4 hours. In patients with impaired renal function with a CC of 20 to 40 ml/min, T1/2 increases to 6.4 hours; with a CC of 5-10 ml/min, it increases to 11.5 hours.
Indications
Infectious and inflammatory diseases caused by susceptible microorganisms: pharyngitis, tonsillitis, sinusitis, acute and chronic bronchitis, otitis media, uncomplicated urinary tract infections, uncomplicated gonorrhea.
ICD codes
| ICD-10 code | Indication |
| A54 | Gonococcal infection |
| H66 | Suppurative and unspecified otitis media |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J03 | Acute tonsillitis |
| J04 | Acute laryngitis and tracheitis |
| J15 | Bacterial pneumonia, not elsewhere classified |
| J20 | Acute bronchitis |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J35.0 | Chronic tonsillitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| N10 | Acute tubulointerstitial nephritis (acute pyelonephritis) |
| N11 | Chronic tubulointerstitial nephritis (chronic pyelonephritis) |
| N30 | Cystitis |
| N34 | Urethritis and urethral syndrome |
| N37.0 | Urethritis in diseases classified elsewhere |
| N41 | Inflammatory diseases of prostate |
| N77.1 | Vaginitis, vulvitis and vulvovaginitis in infectious and parasitic diseases classified elsewhere |
| ICD-11 code | Indication |
| 1A7Z | Gonococcal infection, unspecified |
| 1F23.10 | Candidiasis of vulva and vagina |
| 1F65 | Enterobiasis |
| 1H0Z | Unspecified infection |
| AA9Z | Unspecified suppurative otitis media |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA03.Z | Acute tonsillitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0F.Y | Other specified chronic diseases of the palatine tonsils and adenoids |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA40.0Z | Bacterial pneumonia, unspecified |
| CA42.Z | Acute bronchitis, unspecified |
| GA91.Z | Inflammatory and other diseases of prostate, unspecified |
| GB50 | Acute tubulo-interstitial nephritis |
| GB51 | Acute pyelonephritis |
| GB55.Z | Chronic tubulo-interstitial nephritis, unspecified |
| GB5Z | Renal tubulo-interstitial diseases, unspecified |
| GC00.Z | Cystitis, unspecified |
| GC02.1 | Nonspecific urethritis |
| GC02.Z | Urethritis and urethral syndrome, unspecified |
| 1A94.0 | Genital or urogenital tract infection caused by Herpes simplex virus |
| GA41 | Ulcerative or erosive diseases of vulva |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Tablets, Capsules, Granules
For adults and children over 12 years of age weighing more than 50 kg, the daily dose is 400 mg (once a day or 200 mg twice a day). The duration of the course of treatment is 7-10 days. For uncomplicated gonorrhea – 400 mg as a single dose.
For children under 12 years of age – 8 mg/kg of body weight once a day or 4 mg/kg every 12 hours.
For infections caused by Streptococcus pyogenes, the course of treatment should be at least 10 days.
In case of impaired renal function (with CC from 21 to 60 ml/min) or in patients on hemodialysis, the daily dose should be reduced by 25%.
With CC≤20 ml/min or in patients on peritoneal dialysis, the daily dose should be halved.
Adverse Reactions
From the digestive system: dry mouth, anorexia, diarrhea, nausea, vomiting, abdominal pain, flatulence, transient increase in the activity of hepatic transaminases and alkaline phosphatase, hyperbilirubinemia, jaundice, gastrointestinal candidiasis, dysbacteriosis; rarely – stomatitis, glossitis, pseudomembranous enterocolitis.
From the hematopoietic system: leukopenia, thrombocytopenia, neutropenia, hemolytic anemia.
From the central nervous system: dizziness, headache.
From the urinary system: interstitial nephritis.
Allergic reactions: skin itching, urticaria, skin hyperemia, eosinophilia, fever.
Contraindications
Hypersensitivity to cephalosporins and penicillins.
Use in Pregnancy and Lactation
Use during pregnancy is possible only if the intended benefit to the mother outweighs the potential risk to the fetus.
If it is necessary to use during lactation, breastfeeding should be discontinued.
Use in Renal Impairment
In case of impaired renal function (with CC from 21 to 60 ml/min) or in patients on hemodialysis, the daily dose should be reduced by 25%. With CC≤20 ml/min, the daily dose should be halved.
Pediatric Use
Should be used with caution in children under 6 months of age.
Geriatric Use
Should be used with caution in elderly patients.
Special Precautions
Should be used with caution in elderly patients, patients with chronic renal failure or a history of pseudomembranous colitis, and in children under 6 months of age.
With prolonged use, disruption of the normal intestinal microflora is possible, which can lead to the growth of Clostridium difficile and cause the development of severe diarrhea and pseudomembranous colitis.
In patients with a history of allergic reactions to penicillins, manifestations of hypersensitivity to cephalosporin antibiotics are possible.
During treatment, a positive direct Coombs test and a false-positive urine glucose reaction are possible.
Storage Conditions
Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical DisclaimerBrand (or Active Substance), Marketing Authorisation Holder, Dosage Form
Granules for the preparation of an oral suspension 100 mg/5 ml: bottle 30.3-35.0 g with a dosing syringe
Marketing Authorization Holder
Astellas Pharma Europe B.V. (Netherlands)
Manufactured By
Facta Farmaceutici, S.p.A. (Italy)
Or
Jazeera Pharmaceutical Industries (Saudi Arabia)
On Behalf Of
ASTELLAS PHARMA EUROPE, B.V. (Netherlands)
Packaging and Quality Control Release
HIKMA PHARMACEUTICALS (Jordan)
Or Packaging and Production Quality Control
FACTA FARMACEUTICI, S.P.A. (Italy)
Dosage Form
| Suprax® | Granules for the preparation of an oral suspension 100 mg/5 ml: bottle 30.3-35.0 g with a dosing syringe |
Dosage Form, Packaging, and Composition
Granules for the preparation of an oral suspension from almost white to cream-colored, fine; after mixing, a suspension from almost white to cream-colored with a sweet strawberry aroma is formed.
| 1 bottle | 5 ml of prepared susp. | |
| Cefixime trihydrate (micronized) | 1.402 g | 100 mg |
| (equivalent to 1.2 g of cefixime + 4% overfill) | ||
Excipients: sodium benzoate – 0.03 g, sucrose – 30.225 g, xanthan gum – 0.155 g, strawberry flavor – 0.048 g.
30.3-35.0 g – dark glass bottles (1) complete with a 5 ml dosing syringe – cardboard packs.
Capsules 400 mg: 6 pcs.
Marketing Authorization Holder
Cheplapharm Arzneimittel, GmbH (Germany)
Manufactured By
ACS Dobfar, S.p.A. (Italy)
Dosage Form
| Suprax® | Capsules 400 mg: 6 pcs. |
Dosage Form, Packaging, and Composition
Capsules hard, size “0”, with a purple cap and a white body; with the code “H808” printed with food ink; capsule contents – a yellowish-white mixture of powder and granules.
| 1 caps. | |
| Cefixime trihydrate | 466 mg, |
| Equivalent to cefixime content | 400 mg |
Excipients: colloidal silicon dioxide, magnesium stearate, macrogol glyceryl hydroxystearate (polyoxyl 40 stearate), calcium carmellose (calcium carboxymethylcellulose).
Composition of gelatin capsules: titanium dioxide, dye azorubine (E122), indigo carmine (E132), gelatin.
Composition of food ink: shellac, ethanol, isopropanol, butanol, propylene glycol, sodium hydroxide, povidone, titanium dioxide.
6 pcs. – blisters (1) – cardboard packs.
Granules for the preparation of an oral suspension 100 mg/5 ml: bottle 30.3-35.0 g with a dosing syringe
Marketing Authorization Holder
Cheplapharm Arzneimittel, GmbH (Germany)
Manufactured By
ACS Dobfar, S.p.A. (Italy)
Dosage Form
| Suprax® | Granules for the preparation of an oral suspension 100 mg/5 ml: bottle 30.3-35.0 g with a dosing syringe |
Dosage Form, Packaging, and Composition
Granules for the preparation of an oral suspension from almost white to cream-colored, fine; after mixing, a suspension from almost white to cream-colored with a sweet strawberry aroma is formed.
| 1 bottle | 5 ml of prepared susp. | |
| Cefixime trihydrate (micronized) | 1.402 g | 100 mg |
| (equivalent to 1.2 g of cefixime + 4% overfill) | ||
Excipients: sodium benzoate – 0.03 g, sucrose – 30.225 g, xanthan gum – 0.155 g, strawberry flavor – 0.048 g.
30.3-35.0 g – dark glass bottles (1) complete with a 5 ml dosing syringe – cardboard packs.
Dispersible tablets 400 mg: 1, 5, 7 or 10 pcs.
Marketing Authorization Holder
Cheplapharm Arzneimittel, GmbH (Germany)
Manufactured By
A.Menarini Manufacturing Logistics and Services, S.r.l. (Italy)
Packaging and Quality Control Release
A.Menarini Manufacturing Logistics and Services, S.r.L. (Italy)
Or
ORTAT, JSC (Russia)
Dosage Form
| Suprax® Solutab® | Dispersible tablets 400 mg: 1, 5, 7 or 10 pcs. |
Dosage Form, Packaging, and Composition
Dispersible tablets light orange in color, oblong, with a score line on both sides, with a strawberry odor.
| 1 tab. | |
| Cefixime trihydrate | 447.7 mg, |
| Equivalent to cefixime content | 400 mg |
Excipients: microcrystalline cellulose – 44.5 mg, low-substituted hypromellose – 40 mg, colloidal silicon dioxide – 5 mg, povidone – 5 mg, magnesium stearate – 10 mg, calcium saccharin tris sesquihydrate – 20 mg, strawberry flavor FA15757 – 5 mg, strawberry flavor PV4284 – 2.5 mg, dye “sunset yellow” (E110) – 0.3 mg.
1 pc. – blisters (1) – cardboard packs.
5 pcs. – blisters (1) – cardboard packs.
5 pcs. – blisters (2) – cardboard packs.
7 pcs. – blisters (1) – cardboard packs.
